SyStemix (US) tests stem cell sorter in myeloma patients:
This article was originally published in Clinica
Executive Summary
SyStemix (US) says it has approval to commence US and European trials of its haematopoeitic stem cell (HSC) sorter in multiple myeloma patients. Dr Chris Reading, director of cell processing at SyStemix, says the sorter can isolate HSCs at speeds up to 30,000 cell a second and can produce 90%-pure cell populations, free of tumour cells from multiple myeloma patients' blood, in a single step.